mRNA therapy company SRTD Biotech has completed a €31.5 million seed round financing, led by Mérieux Equity Partners

SRTD Biotech, a German mRNA therapy company, has completed an oversubscribed seed round financing of 31.5 million euros, led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund co-leading.

The funds will be used to advance the seRNA platform that expresses only in diseased cells and LNP delivery.